An official website of the United States government
Home
Name
Gemcitabine
Alternate Names
Gemcitabine Hydrochloride
Gemzar
LY 188011
LY-188011
LY188011 hydrochloride
Gemcitabine HCL
Inlexzo intravesical system
Abbreviations
None
Category
Chemotherapy
Subcategory
Antimetabolite
NSC Number
613327
Primary Site
Histology
None
Remarks
FDA approved for breast. ovarian, pancreas, NSC lung
Gemcitabine HCL is given intravesically as treatment for bladder tumors. Code as chemotherapy.
On September 9, 2025, the FDA approved gemcitabine intravesical system (Inlexzo) for adults with Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors.
Gemcitabine HCL is given intravesically as treatment for bladder tumors. Code as chemotherapy.
On September 9, 2025, the FDA approved gemcitabine intravesical system (Inlexzo) for adults with Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors.
Coding
This drug should be coded
